Hypoxic burden to guide CPAP treatment allocation in patients with obstructive sleep apnoea: a Post-hoc study of the ISAACC trial.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Pinilla, Lucia
  • Esmaeili, Neda
  • Labarca, Gonzalo
  • Torres, Gerard
  • Gracia-Lavedan, Esther
  • Minguez, Olga
  • Martinez, Dolores
  • Abad, Jorge
  • Jose Masdeu, Maria
  • Mediano, Olga
  • Munoz, Carmen
  • Cabriada, Valentin
  • Duran-Cantolla, Joaquin
  • Mayos, Merce
  • Coloma, Ramon
  • Montserrat, Josep Maria
  • de la Pena, Monica
  • Hu, Wen-Hsin
  • Messineo, Ludovico
  • MohammadReza, Sehhati
  • Wellman, Andrew
  • Redline, Susan
  • Sands, Scott
  • Barbe, Ferran
  • Sanchez-de-la-Torre, Manuel
  • Azarbarzin, Ali

Grupos

Abstract

Hypoxic burden (HB) has emerged as a strong predictor of cardiovascular risk in obstructive sleep apnoea (OSA). We aimed to assess the potential of HB to predict the cardiovascular benefit of treating OSA with continuous positive airway pressure (CPAP).Post-hoc analysis of the ISAACC trial (NCT01335087), including non-sleepy patients with acute coronary syndrome (ACS) diagnosed with OSA (apnoea-hypopnoea index =15 events·h-1) by respiratory polygraphy. Patients were randomised to CPAP or Usual Care and followed for a minimum of 1 year. HB was calculated as the total area under all automatically-identified desaturations divided by total sleep time. Patients were categorised as having high or low baseline HB according to the median value (73.1%min·h-1). Multivariable Cox regression models were used to assess whether the effect of CPAP on the incidence of cardiovascular outcomes was dependent on the baseline HB level.The population (362 patients assigned to CPAP and 365 to Usual Care) was middle-aged, overweight/obese, and mostly males. A significant interaction was found between the treatment arm and the HB categories. In the high HB group, CPAP treatment was associated with a significant reduction in the incidence of cardiovascular events [HR (95% CI)=0.57 (0.34 to 0.96)]. In the low HB group, CPAP-treated patients exhibited a trend toward a higher risk of cardiovascular outcomes than those receiving Usual Care [HR (95% CI)=1.33 (0.79 to 2.25)]. The differential effect of the treatment depending on the baseline HB level followed a dose-response relationship.In non-sleepy ACS patients with OSA, high HB levels were associated with a long-term protective effect of CPAP on cardiovascular prognosis.

Copyright ©The authors 2023.

Datos de la publicación

ISSN/ISSNe:
0903-1936, 1399-3003

EUROPEAN RESPIRATORY JOURNAL  EUROPEAN RESPIRATORY SOC JOURNALS LTD

Tipo:
Article
Páginas:
-
PubMed:
37734857
Factor de Impacto:
4,336 SCImago
Cuartil:
Q1 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Keywords

  • POSITIVE AIRWAY PRESSURE; TO-SEVERE OSA; CARDIOVASCULAR OUTCOMES; ASYMPTOMATIC PATIENTS; BLOOD-PRESSURE; MODERATE; DISEASE; HYPERTENSION; ASSOCIATION; PREVENTION

Campos de Estudio

Proyectos y Estudios Clínicos

INTENSIFICACION DR. MIGUEL MARTINEZ GARCIA

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

INT11/037 . 2012

ASOCIACION ENTRE TRASTORNOS RESPIRATORIOS DEL SUEÑO Y TASA DE CRECIMIENTO DEL MELANOMA CUTANEO

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI12/01363 . INSTITUTO DE SALUD CARLOS III . 2013

EFECTO DEL TRATAMIENTO CON CPAP SOBRE LAS CIFRAS TENSIONALES EN PACIENTES CON HIPERTENSION ARTERIAL REFRACTARIA. ESTUDIO MULTICENTRICO Y ALEATORIZADO. ESTUDIO HIPARCO

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI09/01647 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010

INTENSIFICACION DR. MIGUEL ANGEL MARTINEZ GARCIA

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

INT14/00003 . INSTITUTO DE SALUD CARLOS III . 2015

ASOCIACIÓN ENTRE LOS TRASTORNOS RESPIRATORIOS DEL SUEÑO Y EL PRONÓSTICO DEL MELANOMA. ESTUDIO LONGITUDINAL Y MULTICÉNTRICO EN 443 PACIENTES CON MELANOMA CUTÁNEO MALIGNO.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI16/01772 . INSTITUTO DE SALUD CARLOS III . 2017

P4COPD: Prediction, Prevention, Personalized and Precision management of COPD in young adults.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PMP21/00090 . INSTITUTO DE SALUD CARLOS III . 2022

Registro nacional de antibóticos inhalados en patología crónica de la vía área.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

REPAIR . 2023

Cita

Compartir